Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD5 expression in thymic carcinoma

T Hishima1, M Fukayama, M Fujisawa

  • 1Department of Pathology, Tokyo Metropolitan Komagome Hospital, Japan.

The American Journal of Pathology
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A study on urinary free gamma-carboxyglutamic acid in patients with idiopathic urinary calcium stone].

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology·1992
Same author

The carboxyl terminus of RAP30 is similar in sequence to region 4 of bacterial sigma factors and is required for function.

The Journal of biological chemistry·1992
Same author

Protein kinase C mutants in the auto-inhibitory region exhibit two distinct properties.

FEBS letters·1992
Same author

Age-related phenomena in the lumbar intervertebral discs. Lipofuscin and amyloid deposition.

Spine·1992
Same author

Use of mammalian cell expression cloning systems to identify genes for cytokines, receptors, and regulatory proteins.

Current opinion in biotechnology·1992
Same author

Changes in growth-plate morphology associated with rejection of rat-limb allografts.

The Journal of bone and joint surgery. American volume·1992

CD5, a T-cell growth receptor, is expressed in overt thymic carcinoma and atypical thymoma but not typical thymoma. This finding may indicate CD5

Area of Science:

  • Immunohistochemistry
  • Oncology
  • Cellular Biology

Background:

  • Thymic epithelial tumors encompass thymoma and thymic carcinoma.
  • Distinguishing between these entities is crucial for prognosis and treatment.
  • Cellular markers can aid in differentiating thymic neoplasms.

Purpose of the Study:

  • To investigate the differential expression of lymphocyte markers in thymic carcinoma versus thymoma.
  • To identify specific cellular markers that distinguish overt thymic carcinoma (OC) from atypical and typical thymoma.
  • To explore the potential role of CD5 in the pathogenesis of thymic epithelial tumors.

Main Methods:

  • Immunohistochemical analysis of 23 thymic epithelial tumors (7 OC, 5 atypical thymoma, 11 typical thymoma) using a panel of lymphocyte markers.

Related Experiment Videos

  • Double labeling immunofluorescence to confirm co-expression of CD5 and cytokeratin.
  • Molecular size analysis of CD5 in OC tumors.
  • Comparison of CD5 expression in thymic tumors with carcinomas of other organs.

    • Main Results:

    • CD5 was expressed in neoplastic epithelial cells of OC (7/7) and atypical thymoma (2/5), but not in typical thymoma (0/11).
    • CD5 expression was confirmed in cytokeratin-positive cells, indicating its presence on thymic epithelial cells.
    • CD5 from OC tumors exhibited similar molecular size to splenic CD5; CD72 was absent in thymic epithelial cells.
    • CD5 expression was specific to thymic epithelial tumors and not found in other tested carcinomas.

    Conclusions:

    • CD5 expression is a distinguishing feature between thymic carcinoma and typical thymoma.
    • CD5 may play a role in the morphological changes and evolution of overt thymic carcinoma.
    • CD5 expression in neoplastic thymic epithelial cells suggests its involvement in tumor development.